. 2018 Jan 10;9(7):7623–7630. doi: 10.18632/oncotarget.24143

Table 4. Incidence and subhazard ratios of ischemic stroke between cancer patients with and without atrial fibrillation according to CHA₂DS₂-VASc score with the use of the competing-risk regression model.

	Atrial fibrillation
	No				Yes
CHA₂DS₂-VASc score	Event	Rate^#	Crude SHR (95% CI)	Adjusted SHR^† (95% CI)	Event	Rate^#	Crude SHR (95% CI)	Adjusted SHR^† (95% CI)
0∼1	4887	37.6	1 (Reference)	1 (Reference)	74	188.8	4.67 (3.71, 5.87)^***	4.15 (3.29, 5.23)^***
2∼3	8809	120.2	1 (Reference)	1 (Reference)	440	290.1	1.98 (1.80, 2.18)^***	1.95 (1.77, 2.14)^***
4∼5	3736	174.7	1 (Reference)	1 (Reference)	506	362.5	1.84 (1.67, 2.01)^***	1.86 (1.69, 2.04)^***
>5	184	57.9	1 (Reference)	1 (Reference)	54	114.3	1.78 (1.32, 2.41)^***	1.82 (1.34, 2.47)^***

Rate^#, per 1,000 person-year; Crude SHR, crude subhazard ratio.

^†Adjusted for hyperlipidemia, chronic obstructive pulmonary disease, chronic kidney disease, hyperthyroidism, sleep disorder and gout; further controlling for death to estimate adjusted subhazard ratio.

^***p < 0.001.

Table 4. Incidence and subhazard ratios of ischemic stroke between cancer patients with and without atrial fibrillation according to CHA2DS2-VASc score with the use of the competing-risk regression model.

Table 4. Incidence and subhazard ratios of ischemic stroke between cancer patients with and without atrial fibrillation according to CHA₂DS₂-VASc score with the use of the competing-risk regression model.